EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Dynamics of QuantiFERON-TB Gold Plus Results in a Large TB Preventive Treatment Trial Across 3 High-Burden HIV/TB Countries

Belén Saavedra-Cervera iD, Dinis Nguenha, Violet Chihota, Getnet Yimer, Carlos Fernández-Escobar, Kathy Mngadi iD, William Brumskine iD, Neil Martinson iD, Shu-Hua Wang iD, LeeAnne Masilela, Zainab Waggie, Leonardo Martínez iD und 9 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag165 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Belén Saavedra-Cervera und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tuberculosis, Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique. Hauptthemen laut MEDLINE: Antitubercular Agents, HIV Infections, Interferon-gamma Release Tests, Tuberculosis. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We report the longitudinal analysis of QuantiFERON-TB Gold Plus (QFT-Plus) results from a clinical trial conducted in 3 countries with a high tuberculosis (TB)/human immunodeficiency virus (HIV) burden, comparing 3 different TB preventive treatment (TPT) regimens in people with HIV (PWH).

Methods

PWH were enrolled in Ethiopia, Mozambique, and South Africa and randomized to (i) 1 course of weekly rifapentine-isoniazid for 3 months (3HP), (ii) weekly rifapentine-isoniazid for 3 months given annually for 2 years (p3HP), or (iii) daily isoniazid for 6 months (6H). QFT-Plus testing was performed at baseline, month 12, and month 24. Quantitative and qualitative results, and serial changes (conversions and reversions) were assessed.

Results

From baseline to month 12, 13.0% (196/1502) of participants converted, with no differences between 3HP (13.1%) and 6H (12.9%). From month 12 to month 24, conversion occurred in 4.0% of participants receiving a second course of 3HP (p3HP arm), and in 9.4% of those not receiving a second course (3HP) (P = .110). Overall reversions occurred in 19.0% (178/935) of participants. Reversion rates were similar across study arms and timepoints. The risk of developing TB during the study period was higher among individuals who were QFT-Plus positive at baseline (adjusted hazard ratio, 1.66 [95% confidence interval, 1.41–1.89], P = .034).

Conclusions

QFT-Plus conversions and reversions occurred frequently in PWH and did not differ by TPT regimen or between those who did and did not receive a second course of TPT. The high rate of QFT positivity, along with the large proportion of conversions despite TPT, highlights the complexity of interpreting serial interferon-gamma release assay results in PWH in high-transmission scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsHIV InfectionsInterferon-gamma Release TestsTuberculosisAdultFemaleHumansMaleEthiopiaIsoniazidLongitudinal StudiesMozambiqueRifampinSouth Africa

Stichwörter der Autor:innen

IFN-γQFT-Plusconversionsreversionstuberculosis preventive treatment

Substanzen

Antitubercular AgentsIsoniazidRifampinrifapentine

Autor:innen und Institutionen

  • Department of Tuberculosis, Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
  • Instituto de Salud Global de Barcelona, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, location University of Amsterdam, Amsterdam, The Netherlands.
  • The Aurum Institute, Johannesburg, South Africa.
  • Division of Infectious Diseases, Department of Medicine, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Belén Saavedra-Cervera, Kathy Mngadi, William Brumskine, Neil Martinson, Shu-Hua Wang, Leonardo Martínez, Salome Charalambous, Frank Cobelens, Richard Chaisson, Alison D Grant, Katherine Fielding, Gavin Churchyard

Zitieren

APA

Saavedra-Cervera, B., Nguenha, D., Chihota, V., Yimer, G., Fernández-Escobar, C., Mngadi, K., Brumskine, W., Martinson, N., Wang, S. H., Masilela, L., Waggie, Z., Martínez, L., van den Hof, S., Charalambous, S., Cobelens, F., Chaisson, R., Grant, A. D., Fielding, K., Churchyard, G., …, & WHIP3TB Study Team (2026). Dynamics of QuantiFERON-TB Gold Plus Results in a Large TB Preventive Treatment Trial Across 3 High-Burden HIV/TB Countries. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag165

Vancouver

Saavedra-Cervera B, Nguenha D, Chihota V, Yimer G, Fernández-Escobar C, Mngadi K, et al. Dynamics of QuantiFERON-TB Gold Plus Results in a Large TB Preventive Treatment Trial Across 3 High-Burden HIV/TB Countries. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag165

BibTeX
@article{SaavedraCervera2026,
  author = {Saavedra-Cervera, Belén and Nguenha, Dinis and Chihota, Violet and Yimer, Getnet and Fernández-Escobar, Carlos and Mngadi, Kathy and Brumskine, William and Martinson, Neil and Wang, Shu-Hua and Masilela, LeeAnne and Waggie, Zainab and Martínez, Leonardo and van den Hof, Susan and Charalambous, Salome and Cobelens, Frank and Chaisson, Richard and Grant, Alison D and Fielding, Katherine and Churchyard, Gavin and Garcia-Basteiro, Alberto L and WHIP3TB Study Team, WHIP3TB Study Team},
  title = {Dynamics of QuantiFERON-TB Gold Plus Results in a Large TB Preventive Treatment Trial Across 3 High-Burden HIV/TB Countries},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag165}
}
Kostenlos starten →